{
    "nct_id": "NCT05305989",
    "official_title": "Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213",
    "inclusion_criteria": "Subjects must have been treated with belumosudil for at least 1 of the following:\n\n* Actively receiving belumosudil on Study KD025-208 or Study KD025-213\n* Is in Long-term Follow-up (LTFU) on Study KD025-208 or Study KD025-213. Long-term Follow-up will be defined as the period after ending treatment with belumosudil and until a FFS event occurs.\n* Adult enrolled in the Companion Study under KD025-213 Amendment 2 (01 June 2020) and has received at least 6 months of treatment of belumosudil or is in LTFU\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Female subject who is pregnant or breastfeeding\n* Subject considered unlikely to adhere to treatment and/or follow protocol in the opinion of the Investigator",
    "miscellaneous_criteria": ""
}